Medlinkas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 253,761 | 432,632 | 452,821 | 435,146 | 480,611 | 471,829 | 395,479 | 334,909 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -19,082 | 93,057 | 41,344 | 25,706 | 29,788 | -992 | -21,671 | -21,600 |
| Equity | -3,764 | 89,293 | 87,108 | 93,167 | 103,660 | 86,854 | 65,183 | 43,582 |
| Liabilities | 77,035 | 43,270 | 35,992 | 86,823 | 36,632 | 83,134 | 108,585 | 115,002 |
| Non-current assets | 9,500 | 8,894 | 9,078 | 9,545 | 7,037 | 4,654 | 2,741 | 2,698 |
| Current assets | 63,765 | 123,429 | 113,925 | 168,763 | 131,595 | 163,578 | 169,563 | 154,719 |
| Total assets | 73,265 | 132,323 | 123,003 | 178,308 | 138,632 | 168,232 | 172,304 | 157,417 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 61,318 | 69,579 | 52,949 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +7.0% | +70.5% | +4.7% | -3.9% | +10.4% | -1.8% | -16.2% | -15.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -26.0% | 70.3% | 33.6% | 14.4% | 21.5% | -0.6% | -12.6% | -13.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 104.2% | 47.5% | 27.6% | 28.7% | -1.1% | -33.2% | -49.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -7.5% | 21.5% | 9.1% | 5.9% | 6.2% | -0.2% | -5.5% | -6.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.5 | 0.4 | 0.9 | 0.4 | 1.0 | 1.7 | 2.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 126,881 | 216,316 | 226,411 | 217,573 | 240,306 | 195,237 | 143,811 | 167,455 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Medlinkas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-09-16 | 2025-09-18 | 0.33 |
Medlinkas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-03-27 | 2025-03-27 | 229.7 |
| 2025-03-26 | 2025-03-26 | 132.63 |
| 2025-02-25 | 2025-02-25 | 259.41 |
| 2025-02-20 | 2025-02-24 | 257.26 |
| 2025-02-14 | 2025-02-19 | 188.26 |
| 2025-02-13 | 2025-02-13 | 15.0 |
| 2024-12-31 | 2024-12-31 | 93.91 |
| 2024-12-30 | 2024-12-30 | 93.82 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Medlinkas, UAB (code 303701365) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, revenue amounted to €334.9K, down 15.3% year on year and 29.0% compared with 2023. The company remained loss-making, posting a net loss of €21.6K, with a profit margin of -6.4%. This follows a weaker trajectory from 2023, when revenue was €471.8K and the net loss was only €992, to 2024, when revenue fell to €395.5K and the loss widened to €21.7K. The balance sheet remained moderate in size, with total assets of €157.4K, equity of €43.6K and liabilities of €115.0K at the end of 2025. The equity ratio stood at 27.7% and debt-to-equity at 2.64. Asset turnover was 2.13x, indicating relatively efficient use of assets in generating revenue. Return on equity was -49.6% and return on assets -13.7%. Revenue per employee was €167.5K, while profit per employee was -€10.8K.